DaVita raises 2026 guidance significantly.

DaVita raises 2026 guidance significantly. The dialysis and kidney care provider increased its adjusted operating income outlook to $2.15 billion to $2.25 billion, while projecting adjusted earnings per share between $14.10 and $15.20. The company demonstrated confidence in its operational efficiency improvements, particularly through its AI-powered ScheduleHub platform, which is enhancing workforce productivity across its network. Management also addressed potential headwinds from regulatory changes, including anticipated modifications to the ACA and reimbursement payment adjustments. The raised guidance reflects stronger than expected volume trends and operational execution in the first quarter. Investors should monitor how regulatory developments and reimbursement rate changes impact the company's ability to achieve these targets throughout the year.